Loading organizations...
§ Venture Capital · Palo Alto, CA, USA
Prospect Venture Partners is a Palo Alto, California based venture capital firm<br>with over $1B of capital under management.
Key people at Prospect Venture Partners.
Prospect Venture Partners was founded in 1997 by Jim Tananbaum (Co-Founder and Managing Director PVP2 & PVP3).
Prospect Venture Partners operates as a dedicated life sciences venture capital firm. The firm specializes in investing in and cultivating innovative biomedical companies, providing capital and strategic partnership from seed through growth stages. They focus on leveraging their industry contacts and expertise to advise and assist exceptional executive teams within the health care, biotechnology, and medical device spheres.
The firm was co-founded by Alexander E. Barkas and David Schnell, MD, with Russell Hirsch also a significant team member. Their approach stems from the conviction that extraordinary entrepreneurs and executives are the paramount asset in constructing successful businesses. This insight drives their model of actively participating with management teams, offering deep experience and networks to foster innovation and accomplishment within their portfolio.
Prospect Venture Partners serves a clientele of early-stage to growth-stage companies. The firm aims to add substantial value beyond capital, offering strategic guidance and access to talent to ensure entrepreneurial teams have comprehensive resources. Their long-term vision centers on building outstanding biomedical enterprises by empowering these teams to achieve significant advancements and sustained success.
Key people at Prospect Venture Partners.
Prospect Venture Partners is a Palo Alto-based venture capital firm managing over $1 billion in capital, specializing in early- to growth-stage investments in the life sciences sector, particularly biomedical innovation. Their mission centers on building outstanding biomedical companies by partnering with exceptional teams to advance biopharmaceuticals, medical devices, diagnostics, and healthcare services. The firm supports companies addressing critical medical needs, contributing significantly to the startup ecosystem by enabling breakthroughs in genetic diseases, oncology, and other therapeutic areas[1][5].
Founded in the late 1990s, Prospect Venture Partners was co-founded by Russell Hirsch, David Schnell, and the late Alex Barkas. The firm evolved from early investments in healthcare software and medical devices to a focused strategy on biopharmaceuticals and biomedical innovation. Their approach includes investing $3 million to $20 million per company, often taking board seats and actively guiding portfolio companies through various stages of development and financing[3][5].
Prospect Venture Partners rides the ongoing trend of biomedical innovation driven by advances in genomics, targeted therapies, and medical devices. The timing is critical as healthcare increasingly integrates precision medicine and novel therapeutics, creating demand for specialized capital and expertise. The firm influences the ecosystem by nurturing startups that address unmet medical needs, accelerating the translation of scientific discoveries into commercial products, and fostering collaborations across biotech and pharma sectors[1][2][5].
Looking ahead, Prospect Venture Partners is poised to continue leveraging its deep biomedical expertise to back transformative healthcare companies, especially as personalized medicine and digital health converge. Trends such as gene editing, immunotherapies, and AI-driven diagnostics will likely shape their investment focus. Their influence is expected to grow as they help scale startups that redefine treatment paradigms, maintaining a leadership role in life sciences venture capital[1][2][5]. This aligns with their foundational mission of building outstanding biomedical companies that make a meaningful impact on human health.
Prospect Venture Partners was founded in 1997 by Jim Tananbaum (Co-Founder and Managing Director PVP2 & PVP3).
Prospect Venture Partners has 15 tracked investments across 8 companies. The latest tracked deal is $35.0M Series D in SentreHEART in September 2016.
